Pseudomyxoma peritonei medical therapy

Jump to navigation Jump to search

Pseudomyxoma peritonei Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Pseudomyxoma peritonei from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pseudomyxoma peritonei medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pseudomyxoma peritonei medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pseudomyxoma peritonei medical therapy

CDC on Pseudomyxoma peritonei medical therapy

Pseudomyxoma peritonei medical therapy in the news

Blogs on Pseudomyxoma peritonei medical therapy

Directions to Hospitals Treating Pseudomyxoma peritonei

Risk calculators and risk factors for Pseudomyxoma peritonei medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]

Overview

Pseudomyxoma peritonei (PMP) is a rare condition consisting of intraperitoneal mucinous tumors and ascites, most commonly arising from mucinous tumors of the appendix and less commonly from ovary and colon. Pseudomyxoma peritonei symptoms include abdominal distention, bloating, hernia, and infertility. It is a very uncommon tumor with an incidence of 0.1 people per 100,000 per year, slightly more common in the female gender with a median age of 50 years at the time of diagnosis. Prognosis is good in general. Pseudomyxoma peritonei is histologically classified into disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis(PMCA). Mainstay of treatment is cytoreduction surgery combined with hyperthermic intraperitoneal chemoperfusion (HIPEC).

Medical Therapy

Mainstay of treatment for pseudomyxoma peritonei is cytoreductive surgery combined with intraperitoneal chemotherapy with mitomycin at 42°C.[1][2][3]

References

  1. Chen, Chin-Fan; Huang, Che-Jen; Kang, Wan-Yi; Hsieh, Jan-Sing (2008). "Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin / fluorouracil /leucovorin (FOLFOX4)". World Journal of Surgical Oncology. 6 (1): 118. doi:10.1186/1477-7819-6-118. ISSN 1477-7819.
  2. Sugarbaker, Paul H (2006). "New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?". The Lancet Oncology. 7 (1): 69–76. doi:10.1016/S1470-2045(05)70539-8. ISSN 1470-2045.
  3. Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M (2009). "Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience". In Vivo. 23 (4): 639–44. PMID 19567401.


Template:WikiDoc Sources